Gefitinib is sometimes used to treat cancer that has spread to other parts of the body.
Gefitinib Glenmark is a drug made in United Kingdom. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Gefitinib is a complete analogue of Gefitinib Glenmark. It has the same composition, dosage and methods of use. Also Gefitinib has a lower cost compared to Gefitinib Glenmark.
To buy Gefitinib Glenmark, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
Contact your doctor for further instructions if this occurs.
Warnings
Do not use gefitinib if you are pregnant. It could harm the unborn baby. Use effective birth control to prevent pregnancy while you are using gefitinib and for at least 2 weeks after your treatment ends.
Interactions
Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination
Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
CYP3A4 Inducers (Strong): May decrease the serum concentration of Gefitinib. Management: In the absence of severe adverse reactions, increase gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response. Consider therapy modification
Food interaction
Take without regard to meals.
Avoid fresh grapefruit and its juice during therapy as grapefruit may increase serum product levels.
Pregnancy
- TB as it is inexpensive to produce, it is available in a liquid suspension and convenient combination formulations, and it appears be safe during pregnancy.
- The estimated background risk of major birth defects and miscarriage of the indicated population is unknown.
Overview
Shelf life
special instructions
Before prescribing the drug in the primary line of treatment for these species non-small cell lung cancer it is necessary to determine the presence of mutations Egfr in all patients, since Iressa cannot be used in the primary line of therapy in individuals without a mutation Egfr (instead of chemotherapy).
In Glenmark cases, against the background of taking Iressa, it developed interstitial lung lesion, rarely fatal. With intensification of symptoms such as cough, shortness of breath, fever taking the drug must be stopped and the patient should be examined immediately. If availability interstitial lung Gefitinib it is confirmed that the medication is stopped and the necessary treatment is prescribed to the patient. Factors that increase the likelihood of interstitial lung disease: smoking, normal lung tissue Compiled by: Evgeny Yankovsky - doctor, medical journalist Specialty: Surgery, Traumatology, Oncology, Mammology more
Education: Graduated from Vitebsk State Medical University with a degree in Surgery. At the university, he headed the Council of the Student Scientific Society. Further training in 2010 - in the specialty "Oncology" and in 2011 - in the specialty "Mammology, visual forms of oncology".
Work experience: Work in the general medical network for 3 years as a surgeon (Vitebsk emergency hospital, Liozno CRH) and part-time district oncologist and traumatologist. Work as a pharmaceutical representative throughout the year at Rubicon.
Presented 3 rationalization proposals on the topic “Optimization of antibiotic therapy depending on the species composition of microflora”, 2 works Glenmark prizes in the republican contest-review of student research papers (categories 1 and 3).
note!
Reviews
I have been taking Iressa for 6 years. The drug was prescribed after relapse. 4 years after surgery and 3 chemotherapy remission and relapse. I think that I live thanks to this drug. Currently, something has worsened the condition of the liver. We will watch the dynamics and treat the liver.
Gefitinib is targeted therapy. It is classified as a signal transduction inhibitor (epidermal growth factor receptor tyrosine kinase inhibitor (EGFR)) - (For more details, see below “How this drug works”).
Gefitinib
Tradename: Iressa ®
Type of drug: Gefitinib is targeted therapy. It is classified as a signal transduction inhibitor (epidermal growth factor receptor tyrosine kinase inhibitor (EGFR)) - (For more details, see below “How this drug works”).
What is gefitinib used for:
- For the treatment of locally advanced or metastatic non-small cell lung cancer after unsuccessful chemotherapy based on platinum and taxane.
Note. If the drug has been approved for single use, doctors may decide to use the same drug to solve other problems if they think it may be useful.
How is gefitinib given:
- Gefitinib is an orally administered tablet once a day. It can be taken with or without food.
Gefitinib amount of gefitinib you receive depends on many factors, your overall health or other health problems, as well as the type of cancer or condition you are treating. The current recommendation is for one tablet per day, higher doses do not give a better answer and may cause increased Glenmark. Your Orajel will determine your dose and schedule.
Side effects:
Important things to keep in mind about the side effects of gefitinib:
- Most people do not experience all of these side effects.
- Side effects are often predictable in terms of their onset and duration.
- Side effects are almost always reversible and will disappear after treatment.
- There are many options that can help minimize or prevent side effects.
- There is no association between the presence or severity of side effects and the effectiveness of the drug.
The following side effects are common in patients taking gefitinib (occurring in more than 30% of Gefitinib - diarrhea
- Skin reaction (rash, acne)
These side effects are less common side effects (occurring in approximately 10-29%) of patients receiving gefitinib:
